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1. Introduction 
Most drugs used today are purely organic compounds. Especially after the enormous 
success of the cisplatin (Fig 1) in tumor treatment, interest in metal complexes has grown 
(Allardyce & Dyson, 2006). Synthetic organometallic compounds are generally considered to 
be toxic or non-compatible with biological systems. Despite this perception, the medicinal 
properties of organometallic compounds, in particular organo-transition metal compounds, 
have been probed for a long time and in the last few years the area has grown considerably. 
Transition metals have an important place within medicinal biochemistry (Rafique et al, 
2010). Transition metals represent the d block element which includes groups 3 - 12 on the 
periodic table. They have partially filled d-shells in any of their commonly occuring 
oxidation state. Metal complex or coordination compound is a structure consisting of a 
central metal atom, bonded to a surrounding array of ligands (molecules or anions), which 
donate electron pair to the metal. Research has shown significant progress in utilization of 
transition metal complexes as drugs to treat several human diseases like carcinomas, 
lymphomas, infection control, anti-inflammatory, diabetes, and neurological disorders. 
Transition metals exhibit different oxidation states and can interact with a number of 
negatively charged molecules. This activity of transition metals has started the development 
of metal-based drugs with promising pharmacological application and may offer unique 
therapeutic opportunities.  
2. Therapeutic applications of some old and new organometallic complexes 
and discoveries and ongoing studies 
Various metal complexes have been tested in anticancer therapy (Meng et al, 2009). The 
development of metal complexes with platinum central atoms such as cisplatin or 
carboplatin had an enormous impact on current cancer chemotherapy (Fig 1, 2) (Ott & Gust, 
2007). In particular, cisplatin has become one of the most widely used drugs and is highly 
effective in treating several cancers such as ovarian and testicular cancers (Meng et al, 2009). 
 
Fig. 1. Molecular structure of cisplatin. 
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Most of the platinum compounds that entered clinical trials follow the same empirical 
structure-activity relationships (Abu-Surrah & Kettunen, 2006). A necessary prerequisite for an 
active Pt-drug seems to be cis-coordination by bidentate amine ligands or two amines (at least 
one -NH group on the amine) and two leaving groups with an intermediate binding strength 
(e.g. Cl-, SO42-, citrate or oxalate) to platinum. The limitations of cisplatin have stimulated 
research in the field of platinum antitumor chemistry by giving specific goals. These include 
reduction in toxicity of cisplatin (nausea, ear damage, vomiting, loss of sensation in hands, and 
kidney toxicity), acquired drug resistance observed in certain tumors, inefficiency of the drug 
against some of the commonest tumors (e.g. colon and breast). 
 
Fig. 2. Structures of carboplatin (left) and oxaliplatin (right) (Hanif, 2010) 
Thousands of other platinum complexes have been synthesized and biologically evaluated 
for their antitumor properties, from which about fourty entered clinical phase I trials but 
only two carboplatin and oxaliplatin (Fig. 2) have received worldwide approval (Abu-
Surrah & Kettunen, 2006). Carboplatin exhibits a tumor inhibiting profile identical to that of 
cisplatin, however with fewer side effects, whereas oxaliplatin is used in a combination 
therapy against metastatic colorectal cancer. 
Some platinum(II) and palladium(II) complexes with new trans-l-dach (1R,2R-
cyclohexanediamine) based diamine and diimine donor ligands containing the 
enantiomerically pure myrtenyl groups as terminal substituents were synthesized in 2008. 
The anti-proliferative effect of compounds Dichloro[(1R,2R)-(-)-N1,N2-bis{(1R)- 
(-)myrtenyl}-1,2-diamino cyclohexane]-platinum(II).3H2O, Dichloro[1R,2R)-(-)-N1,N2-
bis{(1R)-(-) myrtenylidene}-1,2-diamino cyclohexane]-platinum(II) and Dichloro [(1R,2R)-
(-)-N1,N2-bis{(1R)-(-)myrtenyl}-1,2-diaminocyclohexane]-palladium(II).1.5H2O together 
with the commercial drugs cisplatin (Cis-Pt) and oxaliplatin (Ox-Pt) were investigated in 
L1210 Cell line using 3H-thymidine incorporation (Abu-Surrah et. al., 2008). As shown in 
Figure 3, the platinum compounds Dichloro[(1R,2R)-(-)-N1,N2-bis{(1R)-(-)myrtenyl}-1, 
2-diaminocyclo hexane]-platinum(II).3H2O and Dichloro [1R,2R)-(-)-N1,N2-bis{(1R)-(-) 
myrtenylidene}-1,2-diaminocyclohexane]-platinum(II) suppress proliferation more 
efficiently than the commercial platinum-based drugs with an IC50 of 0.6 and  
0.7 μL, respectively. Compound Dichloro[(1R,2R)-(-)-N1,N2-bis{(1R)-(-) myrtenyl}-1,2-
diaminocyclohexane]- platinum(II).3H2O is 17-folds more potent than the commercial 
oxaliplatin and cisplatin. No significant difference could be observed between the 
complex that contains the diamine nitrogen ligand and the one holding the corresponding 
diimine ligand. The authors also synthesized the palladium complex; Dichloro[(1R,2R)-(-)-
N1,N2-bis{(1R)-(-)myrtenyl}-1,2-diaminocyclohexane]-palladium(II).1.5H2O, which also 
suppresses proliferation efficiently with an IC50 of 4.2 μL. This is about 2-folds more 
potent than the commercial oxaliplatin and cisplatin. 
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(a) Dichloro[(1R,2R)-(-)-N1,N2-bis{(1R)-(-)myrtenyl}-1,2-diamino cyclohexane]-platinum(II).3H2O 
 
(b) Dichloro[1R,2R)-(-)-N1,N2-bis{(1R)-(-) myrtenylidene}-1,2-diamino cyclohexane]-M(II)   M=Pt(II), Pl(II) 
Fig. 3. The structure of some platinum(II) and palladium(II) complexes with new trans-l- 
dach based diamine and diimine donor ligands containing the enantiomerically pure 
myrtenyl groups as terminal substituents (Abu-Surrah & Kettunen, 2006). 
In a total look, platinum complexes display, along with other kinds of anticancer drugs, two 
major drawbacks: (a) severe toxicities (neurotoxicity, nephrotoxicity, etc.) and (b) limited 
applicability to a narrow range of tumors, as several of them exhibit natural or induced 
resistance.  These unresolved problems in platinum-based anticancer therapy have 
stimulated increased research efforts in the search for novel non platinum-containing metal 
species as cytostatic agents. Non-platinum metals may have different chemical behavior 
(oxidation state, redox potential, coordination geometry, additional coordination sites, 
binding preferences to biomolecules according to the HSAB [hard and soft (Lewis) acids and 
bases] principle etc.), rate of hydrolysis or kinetics of ligand exchange reactions and the 
ability to replace essential metals (Abu-Surrah & Kettunen, 2006). Therefore, it is likely that 
non-platinum metal-based compounds may have different mechanisms of action, 
biodistribution and biological activity.  
The antitumor properties of a number of different metal ions and their complexes have been 
evaluated, but only a few non-platinum metal-based drugs are currently in clinical studies, 
the most promising ones contain ruthenium and gallium ions (Abu-Surrah & Kettunen, 
2006). Preclinical and clinical investigations confirmed that the development of new metal 
agents with modes of action different from cisplatin is possible (Ott & Gust, 2007). Thus, 
complexes with iron, cobalt, or gold central atoms have shown promising results in 
preclinical studies and compounds with titanium, ruthenium, or gallium central atoms (as 
in Fig 4)  have already been evaluated in phase I and phase II trials. Other metal complexes 
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that have shown potential anticancer activity are the complexes of Rh(I), Rh(III), Ir(I), Ir(II), 
Ir(IV), Os(II) and Os(III). Many platinum and non-platinum metal complexes such as 
palladium, ruthenium, rhodium, copper, and lanthanum, with aromatic N-containing 
ligands as pyridine, imidazole and 1,10-phenanthroline, and their derivatives (whose donor 
properties are somewhat similar to the purine and pyrimidine bases), have shown very 
promising antitumor properties in vitro and in vivo in cisplatin-resistant model systems or 
against cisplatin-insensitive cell lines (Zhao & Lin, 2005).  
 
 
 
Fig. 4. The chemical structures of titanocene dichloride (a), gold tetraphenylporphyrin (b) 
and gallium maltolate (c) (Hanif, 2010). 
The notable analogy between the coordination chemistry of platinum(II) and palladium(II) 
compounds has advocated studies of Pd(II) complexes as antitumor drugs (Abu-Surrah & 
Kettunen, 2006). A key factor that might explain the reason that platinum is most useful, 
comes from the ligand-exchange kinetics. The hydrolysis of the leaving ligands in palladium 
complexes is too rapid: 105 times faster than their corresponding platinum analogues. They 
dissociate readily in solution leading to very reactive species that are unable to reach their 
pharmacological targets. This implies that if an antitumor palladium drug is to be 
developed, it must somehow be stabilized by a strongly coordinated nitrogen ligand and a 
suitable leaving group. If this group is reasonably non labile, the drug can maintain its 
structural integrity in vivo long enough.  As a way to increase the stability of the 
palladium(II) complexes, two chelates forming two rings around the central atom were 
prepared and evaluated. A series of compounds bearing two chelating ligands the N-N and 
O-O ligand (XO3: selenite or tellurite) were prepared. The N-N ligand did not influence the 
activity but the oxygen coordinated leaving group did. Selenite complexes were invariably 
better cytotoxic agents than tellurite complexes and cisplatin. The complex [bipy)Pd(SeO3)] 
(Fig 5) was found to bind to DNA through a coordinate covalent bond. Another study 
investigated compounds [((1R,2R)-(-)-1,2-diaminocyclohexane)Pd(3-methylorotate)] which 
gave a high activity for sarcoma 180 but a low one against P388 leukemia and [(1R,2R)-(-)-
1,2-diaminocyclohexane)Pd(5-fluroorot)] which also displayed significant antitumor 
activity. These strong chelating ligands replacing chloro or nitro ligands induce a reduction 
in the rate of hydrolysis. 
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Fig. 5. The geometrical structure of [bipy)Pd(SeO3)] (a), [((1R,2R)-(-)-1,2-diaminocyclohexane) 
Pd(3-methylorotate)] (b), [(1R,2R)-(-)-1,2-diaminocyclohexane)Pd(5-fluroorot) (c)] (Abu-
Surrah & Kettunen, 2006) 
Both ruthenium and osmium, along with iron, are members of group VIIIB and are placed 
in the fourth, fifth and sixth row of the periodic table, respectively. They are classified as the 
‘Platinum group’ along with rhodium, palladium, iridium and platinum. All these metals 
often occur together in the same mineral deposits and have closely related physical and 
chemical properties. The application of iron in group 8 metal complexes in anticancer drug 
design is the ferrocenyl derivative of tamoxifen (ferrocifen) (Jauen et al, 2006), and two 
ruthenium containing drug candidates NAMI-A and KP1019 in clinical trials. In trying to 
find better alternatives to tamoxifen, Jaouen et al. (Top et al, 2001), have investigated 
tamoxifen analogs that contain an organometallic moiety. The researchers studied the effects 
of several hydroxy-substituted ferrocifens on the proliferation of two lines of breast cancer 
cells, one used for tumors mediated by the ERǂ receptor, and one used for tumors mediated 
by ERǃ. Three of the ferrocifens (Fig 6) exhibited a strong antiproliferative effect in both cell 
lines while hydroxytamoxifen, as expected, was effective only against the cells having the 
ERǂ receptor. Ferrocifenes exhibit anticancer activity against hormone dependent and 
hormone independent breast cancers (Rafique et al, 2010). The ferrocene derivatives having 
hydroxyl group in phenyl ring have high affinity for estrogen receptor. Ferrocene by itself 
had no effect. 
 
Fig. 6. The main molecular structure of ferrocifenes. 
a b c 
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Special attention has been paid to ruthenium compounds because they exhibit cytotoxicity 
against cancer cells, analogous ligand exchange abilities to platinum complexes, no cross-
resistance with cisplatin, and may display reduced toxicity on healthy tissues by using iron 
transport (Meng et al, 2009).  Ruthenium complexes demonstrate similar ligand exchange 
kinetics to those of platinum(II) antitumor drugs already used in the clinic while displaying 
only low toxicity (Brabec & Novakova, 2006). This is in part due to the ability of ruthenium 
complexes to mimic the binding of iron to molecules of biological significance, exploiting 
the mechanisms that the body has evolved for transport of iron.  
Ruthenium complexes tend to accumulate preferentially in neoplastic masses in comparison 
with normal tissue (Rademaker-Lakhai et al, 2004). They probably use transferrin, for its 
similarities with iron, to accumulate in the tumor. A transferrin-ruthenium complex can be 
actively transported into tumor tissues that have high transferrin-receptor densities. Once 
bound to the transferrin receptor, the complex liberates ruthenium that can be easily 
internalized in the tumor. Next, ruthenium (III) complexes likely remain in their relatively 
inactive ruthenium(III) oxidation state until they reach the tumor site. In this environment, 
with its lower oxygen content and pH than normal tissue, reduction to the more reactive 
ruthenium(II) oxidation state takes place. This reaction, named ”activation by reduction“ 
would provide not only a selective toxicity but also an efficacy toward hypoxic tumors 
known to be resistant to chemotherapy and/or radiotherapy. Finally, some complexes are 
more effective against the tumor metastases than against the primary tumor.  Due to 
differing ligand geometry between their complexes, ruthenium compounds bind to DNA 
affecting its conformation differently than cisplatin and its analogues (Brabec & Novakova, 
2006). In addition, non-nuclear targets, such as the mitochondrion and the cell surface, have 
also been implicated in the antineoplastic activity of some ruthenium complexes. So, 
ruthenium compounds have a pattern of cytotoxicity and antitumor activity that is different 
from that of cisplatin tissue (Rademaker-Lakhai et al, 2004). Ruthenium complexes exhibit 
both nitric oxide release and scavenging functions that can affect vasodilation and synapse 
firing (Clarke, 2003).  Simple ruthenium complexes are unusually effective in suppressing 
the immune response by inhibiting T cell proliferation. Thus, ruthenium compounds offer 
the potential over antitumor platinum(II) complexes currently used in the clinic of reduced 
toxicity, a novel mechanism of action, the prospect of non-cross-resistance and a different 
spectrum of activity. Although the pharmacological target for antitumor ruthenium 
compounds has not been completely identified, there is a large body of evidence indicating 
that the cytotoxicity of many ruthenium complexes correlates with their ability to bind DNA 
although few exceptions have been reported. One of the first ruthenium compounds 
described to have anticancer activity was ruthenium red, and further work showed the 
anticancer potential of ruthenium-containing drugs (Rafique et al, 2010). Since then, several 
teams have synthesized and characterized new compounds containing ruthenium(II) or 
ruthenium(III). Ruthenium red and the related Ru360 strongly inhibit calcium ion uptake in 
the mitochondria (Clarke, 2003).  
Ru(II) and Ru(III) complexes have shown very promising properties while the Ru(III) 
compound NAMI-A (imidazolium trans-[tetrachloro(DMSO)(imidazole)ruthenate(III)]) , is 
the first ruthenium compound that successfully entered phase I clinical trials as an 
antimetastatic drug candidate (Katsaros & Anagnostopoulou, 2002; Antonarakis &  Emadi, 
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2010). Ruthenium compound KP1019 (indazolium trans-[tetrachlorobis(1H-indazole) 
ruthenate(III)]), as an anticancer drug against colon carcinomas and their metastases has 
also entered clinical trials so far. It has shown direct antitumor activity against a wide range 
of primary explants of human tumors by inducing apoptosis (Antonorakis & Emadi, 2010). 
Both compounds showed relatively little side-effects and better tolerance in clinical phase I 
trials (Fig. 7). In preclinical studies, NAMI-A has demonstrated inhibitory effects against the 
formation of cancer metastases in a variety of tumor animal models but appears to lack 
direct cytotoxic effects (Antonarakis &  Emadi, 2010). In case of NAMI-A, DNA is thought to 
be a less important target, and anti-angiogenic activity based on the NO metabolism has 
been described (Bharti & Singh, 2009). NAMI-A interaction with the microenvironment 
involving integrin activation that results in reduced cell invasiveness and migration has 
been proposed and this may be the reasons for the activity of ruthenium compounds against 
cisplatin-resistant tumors. Ruthenium compounds ONCO4417 and DW1/2 have been 
demonstrated to show Pim-1 kinase inhibition in preclinical systems (Sekhon, 2010). A 
phase I and pharmacokinetic study was also carried out with the new ruthenium complex 
indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019, FFC14A) (Lentz et al, 
2009).  Seven patients with various types of solid tumours refractory to standard therapy 
were treated with escalating doses of KP1019 (25-600 mg) twice weekly for 3 weeks. No 
dose-limiting toxicity occurred. Ruthenium plasma concentration-time profiles after the first 
dose and under multiple-dose conditions were analysed using a compartmental approach. 
The pharmacokinetic disposition was characterised by a small volume of distribution, low 
clearance and long half-life. Only a small fraction of ruthenium was excreted renally.  
 
Fig. 7. Structure of ruthenium complexes NAMI-A and KP1019 (Llorca, 2005). 
Many biological properties have been attributed to ruthenium complex I (trans-
[RuCl2(nic)4]) and ruthenium complex II (trans-[RuCl2 (i-nic)4]) including nitric oxide 
synthase inhibition (Valvassori et al, 2006). However, side effects of the ruthenium 
compounds should also be evaluated. In the investigation of the pharmacological effects of 
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these complexes on anxiety and memory formation on adult male Wistar rats, no effects 
were observed in the anxiety parameters and habituation to an open-field while memory 
impairment was observed. The ruthenium complexes impaired memory retention compared 
with vehicle group in the inhibitory avoidance, as when administrated 30 min prior as 
immediately after training. The memory impairment induced by ruthenium complexes may 
be due to their nitric oxide synthase inhibition capacity. 
Rhodium belongs to the same group as platinum and ruthenium. However, rhodium 
compounds, analogues to the corresponding platinum and ruthenium compounds that 
possess significant antitumor properties, were found to be less effective as anticancer agents 
mainly due to their toxic effects. Dimeric mu-Acetato dimers of Rh(II) as well as monomeric 
square planar Rh(I) and octahedral Rh(III) complexes have shown interesting antitumor 
properties.  
In 2009, Meng et al. have studied both in vitro and in vivo the biological properties of 
RDC11 (Fig 8), which contain a covalent  bond between the ruthenium atom and a carbon. 
RDC11 inhibited the growth of various tumors implanted in mice more efficiently than 
cisplatin. Importantly, in striking contrast with cisplatin, RDC11 did not cause severe side 
effects on the liver, kidneys, or the neuronal sensory system. It was shown to interact poorly 
with DNA and induced only limited DNA damages compared with cisplatin, suggesting 
alternative transduction pathways. The target genes of the endoplasmic reticulum stress 
pathway, such as Bip, XBP1, PDI, and CHOP, were activated in RDC11-treated cells. 
Activation of CHOP led to the expression of several of its target genes, including 
proapoptotic genes. Acting through an atypical pathway involving CHOP and endoplasmic 
reticulum stress, RDC11 is thought to provide an interesting alternative for anticancer 
therapy (Meng et al, 2009). 
 
Fig. 8. Molecular structure of RDC11 (Meng et al, 2009). 
A class of ruthenium(II)-arene complexes that are weakly cytotoxic in vitro, were also 
shown to have selective antimetastatic activity in vivo, in the literature (Anga, et. al., 2011). 
These compounds, [Ru(η6-p-arene)Cl2(1,3,5-triaza-7-phosphaadamantane)] termed RAPTA, 
interact strongly with proteins, with the ability to discriminate binding to different proteins, 
but show a relatively low propensity to bind DNA, which is considered to be the main 
target of many metal-based drugs. The basic RAPTA structure is quite stable in 
physiological environments, and studies have shown that aquation of the chloride  
bonds occurs, it may not be an essential step for anticancer drug activity – direct  
substitution with biomolecular targets is also possible. Based on the concept of bifunctional 
radiopharmaceuticals (Ogawa et al, 2007), developed a highly stable 186Re-
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mercaptoacetylglycylglycylglycine (MAG3) complex-conjugated bisphosphonate, [[[[(4-
hydroxy-4,4-diphosphonobutyl) carbamoylmethyl]carbamoylmethyl]carbamoylmethyl] 
carbamoylmethane thiolate] oxorhenium (V) (186Re-MAG3-HBP), for the treatment of 
painful bone metastases. 186Re-MAG3-HBP accumulated at the site where tumor cells were 
injected in a rat model of bone cancer and significantly inhibited tumor growth and 
attenuated the allodynia induced by bone cancer without having critical myelosuppressive 
side effects. The results indicate that 186Re-MAG3-HBP could be useful as a therapeutic 
agent for the palliation of metastatic bone pain. 
Since DNA has often been proposed as the target of these organometallic antineoplastic 
agents, there is a particular emphasis on those that can interact with nucleic acids (Clarke et al, 
1999). Nevertheless, heavy metals are generally toxic by binding to sulfur and nitrogen sites on 
proteins and, thus, can interfere with a number of modes of metabolism. Several metals also 
exhibit action through redox activity. Gallium appears to operate through the displacement of 
metal ions in iron metabolism or bone. In large part, action of gallium complexes seems to be a 
consequence of the similarity of gallium(III) to iron(III): Gallium interferes with the cellular 
transport of iron by binding to transferrin, and also interferes with the action of ribonucleotide 
reductase, which then results in inhibition of DNA synthesis (Hannon, 2007). The key to 
activity is making gallium(III) bioavailable, and work is focused on ligands which  
stabilize gallium against hydrolysis and facilitate membrane permeation. Among the 
developed gallium comounds, tris(8-quinolinolato)gallium(III) (KP46/FFC11) has entered 
clinical trials (Fig 9). 
 
Fig. 9. Molecular structure of Tris(8-quinolinolato)gallium(III)  
Gallium-based anticancer chemotherapeutics are appreciably progressing in clinical studies 
(Timerbaev et al, 2009). The interest of drug developers and clinicians in gallium 
compounds is due to a proven ability of gallium cations to inhibit tumour growth, and 
enhanced bioavailability and moderate toxicity provided by the conversion of gallium into 
chelate complexes. One of the complexes suitable for a more convenient oral administration 
is tris(8-quinolinolato) gallium(III) (KP46). KP46 is an orally bioavailable gallium complex, 
which exerts its antitumoral activity via inhibition of ribonucleotide reductase, induction of 
S phase arrest and apoptosis (Dittrich et al, 2005). In preclinical models KP46 was proved to 
be a stronger anticancer agent than gallium nitrate and it was effective on a model of tumor-
associated hypercalcemia. Nominated from a range of gallium complexes for the clinical 
stage of development, KP46 has finished phase I trials with the outcome of promising 
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tolerability and evidence of clinical activity in renal cell carcinoma (Timerbaev et al, 2009). 
The adverse reactions of the complex, observed in a study, where 7 patients were used were 
neutropenia and anemia, stomatitis and conjunctivitis, dizziness, headache and acne, fatigue 
and diarrhaea both (Dittrich et al, 2005). In one out of the 4 patients with renal cell 
carcinoma an unconfirmed partial response has been observed after 8 weeks and in a second 
patient with renal cell carcinoma the disease was stabilized for 29 weeks. Peak plasma levels 
were reached 5-7 h after intake and pharmacokinetic analysis revealed a long terminal half-
life (28 h). KP46 has been well tolerated with some preliminary evidence of efficacy in renal 
cell carcinoma.  
The low-spin 5d6 IrIII organometallic half-sandwich complexes [(η5-Cpx)Ir(XY)Cl]0/+,  Cpxph : 
tetramethyl(phenyl)cyclopentadienyl, or Cpxbiph: tetramethyl(biphenyl)cyclopentadienyl, XY 
= 1,10-phenanthroline, 2,2′-bipyridine, ethylenediamine, or picolinate, were investigated at 
2011 (Liu et al, 2011). Complexes with N,N-chelating ligands readily form adducts with 9-
ethylguanine but not 9-ethyladenine; picolinate complexes bind to both purines. Cytotoxic 
potency toward A2780 human ovarian cancer cells increases with phenyl substitution on 
Cpx: Cpxbiph > Cpxph . The hydrophobicity and intercalative ability of Cpxph and Cpxbiph make 
a major contribution to the anticancer potency of their IrIII complexes. 
Among the metallocene dihalide complexes MX2Cp2 (where M=Ti, V, Mo, Nb etc., X= halide 
and Cp = η5-cyclopentadienide), titanocene (Fig 10), TiCl2Cp2 or MTK4 is the most 
successful anticancer agent as shown in phase I/II clinical trials (Bharti & Singh,2009). 
Titanocene dichloride had been recognized as active anticancer drug against breast and 
gastrointestinal carcinomas. Previously DNA was supposed to be the target of [TiCl2Cp2] in 
a manner similar to cisplatin due to the similarity in Cl---Cl distances. Later, the aqueous 
chemistry of [TiCl2Cp2] showed that DNA is not the site of action for this drug. The 
anticancer activity of TiCl2Cp2 is due to inhibition of collagenase type IV activity, which is 
involved in regulation of cellular proliferation, protein kinase C and DNA topoisomerase II 
activities. Titanium may also replace iron in transferrin and facilitate cellular uptake into 
tumor cells. The titanocene dichloride is believed to be accumulated via the transferrin–
dependent pathways. Dose limiting toxicities of titanium compounds include nephrotoxicity 
and elevation of creatinine and bilirubin levels.  
 
Fig. 10. Molecular structue of titanocene (Hannon, 2007) 
Budotitane [cis-diethoxybis(1-phenylbutane-1,3-dionato)titanium (IV)] (Fig 11), was the first 
non-platinum transition-metal anticancer agent to be tested in clinical trials (Schilling et al, 
1995). It is effective against a number of tumors in animals and is well tolerated (Bharti & 
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Singh, 2009). In vitro and in vivo experiments with budotitane showed no significant DNA 
damage. The dose-limiting side effects include cardiac arrhythmia, hepatotoxicity, renal 
toxicity and a reversible loss of taste (Dabrowiak, 2009; Antonarakis &  Emadi, 2010). Ti(IV) 
compounds are known to inhibit proteases and telomerases. Inhibition of proteases in 
rapidly growing tumor cells may block the growth of tumor cells. Inhibition of telomerase 
may control all protein synthesis. 
 
Fig. 11. The molecular structure of budotitane (Bharti & Singh, 2009). 
Gold compounds are used for treating arthritis and cancer, they have potential for treating 
AIDS, malaria and Chagas disease (Dabrowiak, 2009). A property of Au+3 that greatly 
complicates its chemistry is that many of its simple complexes can easily be reduced to Au+ 
by a variety of ligands, including thiols and thioethers found on cysteine and methionine 
residues of peptides and proteins. Even the disulfide linkage, R-S-S-R’, which is generally 
considered a poorer ligand than a thiol or a thioether, binds to and reduces Au+3  to Au+. 
Since there are agents in the biological system that can oxidize Au+ to Au+3, gold 
compounds can, in principle, exist in a variety of different coordination states in the 
biological system. These properties, and the fact that the concentrations of gold compounds 
normally encountered in therapeutic situations are very low, make it difficult to determine 
the chemistry of gold in the biological environment. Gold thiolate complexes were found 
especially effective at slowing the progression of rheumatod arthritis. Sodium 
aurothiomalate (myochrysine), aurothioglucose (solganol) and aurothiosulfate 
(sanochrysine) are water-soluble polymeric antiarthritic compounds that are administered 
to the patient by injection, so-called injectable or parenteral drugs, while auranofin, which is 
only slightly soluble in water, is given to the patient orally in capsule form. The earlywork 
on auranofin and its analogs revealed that Au+ complexes that have phosphine and 
thioglucose ligands were effective in killing B16 melanoma and P388 leukemia cells in 
culture. One compound that showed a significantly broader range of activity than auranofin 
and one of its analogs against a number of different tumor models implanted in mice was 
the tetrahedral cation [Au(dppe)2]+, bis[1,2-bis(diphenylphosphino) ethane]gold(I). 
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[Au(dppe)2]+ is active alone, and in combination with cisplatin, against P388 leukemia in 
mice, and it is also active against various sarcomas in mice. The compound aurocyanide, 
[Au(CN)2]-, which is a biotransformation product in chrysotherapy, has been found to 
inhibit proliferation of HIV in a strain of CD4+.  A gold complex with two attached 
thioglucose ligands has been shown to protect MT-4 cells from the HIV virus by binding to a 
specific cysteine residue on a 120 kDa protein, gp120, which is part of the outer envelope of 
the virus. The compound [bpza][AuCl4], where bpza is the diprotonated-chloride form of a 
bis-pyrazole ligand, inhibits both reverse transcriptase and HIV-1 protease. Since these 
enzymes function differently in the life cycle of the HIV virus, inhibiting both with a single 
compound is unusual. Reverse transcriptase is responsible for converting viral RNA into 
double-stranded DNA prior to the integration of the latter into genomic DNA of the T cell, 
and HIV-1 protease controls the maturation and production of infectious virons (virus 
particles). Since [bpza][AuCl4] is nontoxic to peripheral blood mononuclear cells in the 
immune system, the compound is thought to have potential as an anti-HIV agent. 
A recent report by Sannella et al. (Sanella et al, 2008) showed that auranofin and other gold 
compounds inhibit the growth of Plasmodium falciparum, a protozoan parasite carried by 
Anopheles mosquitoes that causes malaria. The researchers suggested that the mechanism 
by which the gold compounds inhibit the growth of P. falciparum is related to the ability of 
the complexes to block the function of the enzyme thioredoxin reductase, TrxR. 
Nickel is an essential component in different types of enzymes such as urease, carbon 
monoxide dehydrogenase, and hydrogenase (Abu-Surrah & Kettunen, 2006). Recently, some 
results showing also apparent potential of this platinum group element in antitumor studies 
have been reported. For example the cytotoxicity of the nickel (II) complexes containing 1,2-
naphtoquinone-based thiosemicarbazone ligands (NQTS) was tested on MCF7 human 
breast cancer cell line and compared to free ligand and another naphthoquinone, 
commercial antitumor drug etoposide. According to the reported data, Ni-NQTS complex 
has the highest antitumor activity with an IC50 of 2.2 μM. The mechanistic study of action 
showed inhibition of topoisomerase II. Recent studies showed that the corresponding nickel 
complexes of semicarbazones (Fig 12) have even greater inhibitory effect on MCF7 cell 
growth. They display IC50 values in 2-5 μM range and also in general they produce lower 
side effect than thiosemicarbazones. 
 
Fig. 12. Structure of a Ni(II)-semicarbazone based antitumor complex  (Abu-Surrah & 
Kettunen, 2006) 
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In 2010, new methoxy-substituted nickel(II)(salophene) derivatives are synthesized and 
their anticancer properties were investigated (Lee et al, 2010). It was demonstrated that the 
most active complex [Ni(II)(3-methoxy-salophene)] (Fig 10) is not necrotic in Burkitt-like 
lymphoma cells (BJAB) and human B-cell precursor cells (Nalm-6). [Ni(II)(3-methoxy-
salophene)] inhibited proliferation and induced apoptosis in a concentration dependent 
manner, giving evidence for the involvement of CD95 receptor-mediated, extrinsic pathway. 
Furthermore, [Ni(II)(3-methoxy-salophene)] overcame vincristine drug resistance in BJAB 
and Nalm-6 cells.  
Organometallic compounds like Iron (III)-salophene with selective cytotoxic and 
antiproliferative properties have also been used in platinum resistant ovarian cancer cells 
(Rafique et al, 2010). 
The low-spin Fe(II) complex sodium nitroprusside (Fig 13)  is a clinically used metal-nitrosyl 
complex (Guo & Sadler, 1999). It is often used to lower blood pressure in humans. Its 
hypotensive effect is evident within seconds after infusion, and the desired blood pressure is 
usually obtained within one to two minutes. It is also useful in cases of emergency 
hypertension, heart attacks, and surgery. Its therapeutic effects depend on release of nitric 
oxide, which relaxes vascular smooth muscle. Activation in vivo may involve reduction to 
[Fe(CN)5(NO)]3-, which then releases cyanide to give [Fe(CN)4(NO)]2- and then nitric oxide. 
 
Fig. 13. Fe(II) complex with nitroprusside 
The low cytotoxicity of ferrocene, coupled with its lipophilicity (logPoctanol/water = 3.28) and 
its electrochemical behaviour (redox potential of the ferrocene/ferrocenium couple,  
E0 =+0.400 V versus SCE (Saturated Calomel Electrode), suggested that this compound 
could yield interesting results if incorporated into a known drug (Blackie & Chibale, 2008). 
The ferrocenyl moiety has several characteristics which make it a good addition to known 
drug molecules. Its lipophilicity, electron density, relative thermal and chemical stability, 
and interesting redox behaviour are all favourable in this respect. There are several reported 
successes of increased efficacy of ferrocenyl analogues of known drugs. Brocard and co-
workers, combined Chloroquine and ferrocene in the same molecule by inserting a 
ferrocenyl group into the side chain of Chloroquine, producing a hybrid compound called 
Ferroquine (Fig 11), which is more potent than Chloroquine. They have shown that 
incorporation of a ferrocenyl moiety as an integral part of the side chain of chloroquine 
between the two nitrogens had superior efficacy to other analogues in which the moiety was 
terminal on the side chain or bonded to the quinoline nitrogen. Some analogues of the 
compound were produced bearing different alkyl groups on the terminal tertiary nitrogen. 
They established that the dimethylamino terminal group was superior in efficacy (Fig 14) 
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Fig. 14. Molecular structure of Chloroquine and Ferroquine. 
The highly established chemistry of ferrocenes that allows an easy and rapid access to a bank 
of reagents and derivatives has given them a considerable role in the field of analytical 
chemistry (Rudrangi et al, 2010). Ferrocene-based derivatization of various functional groups 
and detection techniques is of high interest in particular. The chemistry of ferrocenes is well 
explored and a wide range of ferrocene derivatives are easily obtained through the established 
synthetic routes.The ferrocenes allow the use of a large variety of detection techniques like 
UV/Visible absorption spectroscopy, atomic spectroscopy, atomic absorption spectroscopy 
(AAS), inductively coupled plasma (ICP) excitation with optical emission spectroscopy (OES) 
or mass spectrometry (MS), electron impact or electrospray ionization (ESI) MS, and the 
electrochemical detection (ECD) techniques that include voltammetry or amperometry.  
The role of the length of the methylene spacer between the two nitrogens in chloroquine 
analogues has been shown to have an influence on efficacy in chloroquine resistant strains 
of P. falciparum. Aminoquinolines with short (2-3 carbons) and long (10–12 carbons) 
methylene side chains are equipotent against chloroquine-sensitive, chloroquineresistant, 
and multidrug-resistant strains of P. falciparum. Whilst aminoquinolines with side chains of 
intermediate length (4–8 carbons) showed efficacy against chloroquinesensitive strains of P. 
falciparum, they showed a significant decrease in efficacy against chloroquine-resistant 
strains of P.Falciparum. In the chloroquine-sensitive D10 strain, the longer the methylene 
spacer, the lower the efficacy. It may be that the changes in lipophilicity and pKa values and 
other physicochemical effects of the incorporation of the ferrocenyl moiety into chloroquine 
are the primary factor in the enhanced efficacy of ferroquine. 
As published as a patent application in 2006 (Maurel & Cudennec, 2009), some manganese 
based organometallic complexes having Mn-SOD like activities, pharmaceutical 
compositions and dietetic products for use in oxidative stress, including cancer and 
inflammatory conditions, were also designed. Many human diseases are associated with the 
overproduction of oxygen free radicals that inflict cell damage (Rafique et al, 2010). Primary 
reactive oxygen species (ROS) such as superoxide radical, hydrogen peroxide, hydroxyl 
radicals, and ortho-quinone derivatives of catecholamines exert their cellular effects by 
modifying DNA, lipids, and proteins to form secondary electrophiles (Zhang & Lippard, 
2003). Damage caused by the primary and secondary ROS contributes to the pathogenesis of 
important human diseases. In particular, one consequence of oxidative metabolism is the 
generation of superoxide radicals (O2-.) which mediate extensive damage to the cellular 
components of living organisms. The molecular dismutation of O2-. to hydrogen peroxide 
(H2O2) and oxygen (O2) is catalysed by superoxide dismutases (SODs).These enzymes are 
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suggested to form the first line of the cell's defence against oxygen damage. Indeed, mice 
defective for SOD do not survive and reduction of functional capabilities of this enzyme 
generates an high increase of oxidative stress in connection with strong mitochondrial 
disabilities of cells. Fe-containing SODs (FeSOD) are largely confined to prokaryotes and the 
Cu/Zn enzymes (Cu/ZnSOD) predominantly to eukaryotes. Mn-containing SODs 
(MnSOD) are universally present. In eukaryotes MnSODs are localised in the mitochondria, 
while the Cu/ZnSODs reside in the cytosol. SODs from various sources are currently of 
great interest as potential therapeutic treatments for oxidative damage. SOD has function 
against certain inflammatory processes (In particular, deficiency in Mn-SOD is supposed to 
have some significance in the development of rheumatoid arthritis). SOD has also function 
against inflammatory processes in alcohol-induced liver damage. Additional potential 
therapeutic effects for SOD include: (i) prevention of oncogenesis, tumour promotion and 
invasiveness, and UV-induced damage; (ii) protection of cardiac tissue against post-
ischemia reperfusion damage; (iii) antiinflamatory effect; (iv) reducing the cytotoxic and 
cardiotoxic effects of anticancer drugs; (v) endothelial disorders; (vi) degenerative diseases; 
(vii) coagulation disorders, and; (viii) improving the longevity of living cells. Currently 
bovine Cu/ZnSOD is being utilised for the treatment of inflamed tendons in horses and for 
treating osteoarthritis in man. It has been shown that the mitochondrial antioxidant enzyme 
manganese-containing superoxide dismutase (MnSOD) functions as a tumor suppressor 
gene and that reconstitution of MnSOD expression in several human cancer cell lines leads 
to reversion of malignancy.  
The use of SOD in therapy is limited by its short plasma half-life (clearance by the kidney) 
and inability to penetrate cell membranes (i.e., extracellular activity only) (Guo & Sadler, 
1999). Low molecular mass mimics of SOD are therefore of much potential pharmaceutical 
interest. For example, a variety of Mn- and Fe-based porphyrins and macrocyclic complexes 
exhibit SOD mimic activity. 
Among metal complexes (Cu, Fe, Mn) capable of catalyzing dismutation of the superoxide 
anion, those of manganese are a current focus for developing SOD mimics as drugs because of 
the low in vivo toxicity of this metal ion (Zhang & Lippard, 2003). Mn(II) and Mn(III) 
macrocycles appear to be particularly promising (Guo & Sadler, 1999). For example, a 
manganese (II) complex with bis (cyclohexylpyridine)-substituted macrocyclic ligand has been 
designed as a functional mimic of SOD which was reported to have a significant of 
inflammation and reperfusion injury (Aston et al., 2001, Rafique et al, 2010). This complex has 
remarkably high kinetic and thermodynamic stability with regard to dissociation, is 
oxidatively stable as well and is excreted intact with no dissociation in vivo This stability 
profile shows that this is a catalytically active SOD mimic. Manganese complexes have also 
been used to treat cell and tissue oxidative injuries by acting as superoxide anion scavenger. 
Nitrogen containing macrocyclic complexes of Manganese (II) have shown anti microbial 
activity. An octahedral geometry for these complexes has been confirmed by spectroscopic 
analysis. Many manganese complexes have been screened against a number of pathogenic 
fungi and bacteria to evaluate their growth and potential. Another example to the therapeutic 
effects of manganese complexes is Mn(III)5,10,15,20-tetrakis(4-benzoic acid)-porphyrin, which 
can protect against neurodegeneration and is therefore of potential interest for the treatment of 
brain diseases such as Parkinson and Alzheimer diseases (Meng et al, 2009). Results from 
systematic modification of the porphyrin ligand demonstrate that placement of four positively 
charged ortho-(N-alkyl) pyridyl groups (alkyl: methyl and ethyl) in the meso positions of 
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porphyrin can strongly facilitate the disproportion of O2-., owing to favorable electrostatic 
contributions. SC-52608 (Fig 15) is another complex, able to scavenge superoxide and therefore 
effectively protect the regionally ischemic and reperfused myocardium from injury. Both 
complexes reduced oxidative stress injury in vivo and they have high stability and catalytic 
efficacy (Guo & Sadler, 1999;  Zhang & Lippard, 2003). In the search for a lipophilic manganese 
SOD mimic, a dinuclear manganese(III) complex of biliverdin IX dimethyl ester was 
discovered to have such activity. In this example O2- . dismutation is effected by a 
Mn(III)/Mn(IV) redox couple. In addition, the manganese complex does not bind to NO and 
reacts very slowly with H2O2, demonstrating specificity towards O2-.. 
 
Fig. 15. Molecular structure of SC-52608  (Guo & Sadler, 1999) 
The incorporation of manganese into the structure of antioxidants like pyran, pyridine, 
benzopyran and quinoline i.e., kojic acid, 6-hydroxynicotinic acid, 7-hydroxyflavone, 8-
hydroxyquinoline and 8-hydroxyquinoline ethylenediamine, made the complexes possessed 
the SOD activity and increased radical scavenging activity of antioxidants as expected 
(Vajgupta et al, 2003). Manganese atom is therefore the essential part for SOD action. 7-
hydroxyflavone complex was promising, since it exhibited potent radical scavenging ability 
and suppressed the MAP-induced hypermotility without reducing the locomotor activity in 
normal condition, and also improved the impaired learning and memory in transient 
ischemic mice. 
A new approach involves modelling the pharmacological properties of established drugs 
with organometallic fragments (Ott et al, 2009). The metallocyclic peptide, bacitracin, has an 
interesting SOD activity. The Mn(II)–bacitracin complex (Piacham et al, 2006) (Fig 16, 17) is 
potentially useful as an effective agent against oxidative stress (for O2-. scavenging). On the 
other hand, probably this Mn(II)–bacitracin may be involved in the respiratory burst 
mechanism of white blood cells that could enhance bacterial killing by synergistic process to 
convert superoxide radical into hydrogen peroxide which is used by enzyme 
myeloperoxidase to convert normally unreactive halide ions into reactive hypohalous acids 
that are toxic to bacteria. Also its antibiotic mechanism could be useful for bacterial and 
oxidative stress treatments.  
Bacitracin provides strong affinity to divalent metal ions such as Zn(II), Cu(II), Co(II), and 
Mn(II) in the formation of 1:1 complex. Structural characterization of metallobacitracin 
showed that it is composed of a cyclic heptapeptide and a short N-terminal sequence 
containing a thiazoline ring (Fig 17). The divalent metals interact with the cyclic and the 
linear peptides to form a strong bending structure that encapsulates the metal inside the 
coordination sphere. It is interesting to note that the established order of binding affinity of 
the transition metal ions was found to be inversely correlated with the observed SOD 
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activity reported in this work. The order of metal binding affinity and SOD activity is Cu(II) 
> Ni(II) > Co(II) ≈Zn(II) >Mn(II) (Brabec & Novakova, 2006) and Mn(II) > Cu(II) > Co(II) > 
Ni(II), respectively. However, it should be noted that the negative correlation is valid for 
Mn(II), Co(II), and Ni(II) but not Cu(II).  
 
Fig. 16. Molecular modeling of Mn(II)-bacitracin complex (Piacham et al, 2006) 
 
Fig. 17. Mn(II) ligand models derived from metallobacitracin complexes (Piacham et al, 
2006) 
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It is possible that the observed trend, in which Cu(II)–bacitracin did not follow the order of 
increasing SOD activity with decreasing metal binding affinity, is because Cu(II) takes on a 
different coordination chemistry from the other divalent metal ions in which Cu(II) forms a 
tetragonally distorted geometry with two coordinated nitrogens and two coordinated 
oxygens, particularly, His-10 imidazole nitrogen, thiazoline nitrogen, Glu-4 carboxylate 
oxygen, and Asp-11 carboxylate oxygen. Proton NMR studies established that Co(II) is 
coordinated to three nitrogens and one oxygen, namely, His-10 imidazole nitrogen, 
thiazoline nitrogen, Ile-1 amino nitrogen, and Glu-4 carboxylate oxygen. For the 
construction of the molecular models of metallobacitracin, it was assumed that Mn(II) and 
Ni(II) adopt a similar coordination chemistry to that of Co(II) because they all have a vacant 
d shell. 
Cobalt–aspirin complexes are investigated as potential cytostatics (Ott et al, 2009). Aspirin 
(acetylsalicylic acid) belongs to the family of nonsteroidal antirheumatics (NSAR), which 
have anti-inflammatory and pain-relieving effects The pharmacological effects of NSARs 
stem from the inhibition of enzymes in the cyclooxygenase family (COX). Besides the role of 
NSARs in inflammatory processes, they also seem to be involved in tumor growth. NSARs 
have thus come into focus as potential cytostatics. It may be possible to improve anti-tumor 
activity in the case of aspirin by binding it to an organometallic fragment. A 
hexacarbonyldicobalt–aspirin complex (Fig 18), is shown to inhibit COX activity differently 
from aspirin. Whereas the effect of aspirin stems from the acetylation of a serine residue in 
the active center of COX, Co-Aspirin  complex does not attack this side chain, but acetylates 
several other sites instead. This may block access to the active center of the enzyme, 
resulting in a different activity spectrum for the drug. Experiments with zebra fish embryos 
showed that in contrast to aspirin, Co-Aspirin inhibits both cell growth and the formation of 
small blood vessels (angiogenesis). Tumors are dependent on newly formed blood vessels 
for their nutrients and can be starved out by the inhibition of angiogenesis. In addition, Co-
Aspirin modulates other tumor-relevant metabolic pathways. For example, it activates the 
enzyme caspase, which is involved in processes that lead to apoptosis (programmed cell 
death). 
 
Fig. 18. The structure of  hexacarbonyldicobalt–aspirin complex (Ott et al, 2009)  
Sadler and coworkers (Meggers, 2007) investigated the binding of metal complexes of 
1,4,8,11-tetraazacyclotetradecane (cyclam) macrocycles to the CXCR4 coreceptor and 
lysozyme as a model protein. In such metallocyclam complexes, the metal is supposed to 
function by controlling the conformation and configuration of the macrocycle. Additional 
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direct coordinative bonds with the target protein can be formed with the vacant axial 
coordination sites. One of the most potent members of this family is the xylyl-bicyclam 
AMD3100 (Fig 19), a CXCR4 receptor inhibitor, which is in clinical trials for the treatment of 
AIDS. The anti-HIV activity correlates with its binding to the coreceptor protein CXCR4. 
CXCR4 is a chemokine receptor that transduces signals of its endogenous ligand, 
CXCL12/stromal cell-derived factor-1 (SDF-1) (Tamamura et al, 2006). CXCR4 is classified 
into 7TMGPCR and plays a physiologically critical role by the action of CXCL12 in the 
migration of progenitors during embryologic development of the cardiovascular, 
hemopoietic, central nervous systems, etc. In addition, CXCR4 was previously identified as 
a coreceptor that is used by X4-HIV-1 in its entry into T cells and has recently been proven 
to be involved in several problematic diseases, including HIV infection, metastasis of several 
types of cancer, leukemia cell progression, rheumatoid arthritis. Thus, CXCR4 is thought to 
be a great therapeutic target to overcome these diseases, and several inhibitors directed 
against CXCR4 have been developed to date. Research performed on AMD3100 analogs 
have revealed that if it is complexed with certain metals it will increase the bonding affinity 
to CXCR4 by causing the cyclam rings to take on a folded cis configuration (Snell, 2005). 
When Zn(II)–xylyl-bicyclam binds with acetate, it undergoes a configuration change and 
becomes cis folded.  The cyclam ring can function as a tetradentate coordination ring for 
transition metals, and it has been shown that chelation of such metal ions by the macrocyclic 
rings of AMD3100 alters its binding affinity to the CXCR4 receptor (Gerlach et al, 2003). 
Thus, the Zn2+ complex of AMD3100 binds with a 10-fold higher affinity to the receptor as 
compared to AMD3100 alone and has an up to 6-fold increased potency as an anti-HIV 
agent. Zn2+ is located in the center of the cyclam ring, coordinating the four nitrogens in a 
planar fashion. Since Zn2+ does not coordinate in a square planar conformation, it either 
obtains a square pyramidal or an octahedral geometry with one or two vacant coordination 
sites. Zn2+ has the option to make strong interactions with both histidine and cysteine 
residues, as well as acidic residues such as aspartates. The CXCR4 receptor does not contain 
any free extracellular cysteines; however, the main interaction points for AMD3100 are two 
aspartates, and furthermore, several histidine residues are located in TM-III, TM-V, and TM-
VII (TM: transmembrane domain) pointing toward the main ligand binding crevice (Figure 
20). Thus, metal ion coordination could either improve the binding mode of AMD3100 to 
one or more of the two aspartates, Asp171 and Asp262, or it could pick up interaction with 
one or more of the His residues that potentially could serve as partners in the coordination 
of Zn2+ bound by the bicyclam. 
The level of anti-HIV activity expressed by these metal complexes were Zn>Ni>Cu>Co>Pd 
in decreasing order. The affinity of AMD3100, a symmetrical nonpeptide antagonist 
composed of two 1,4,8,11-tetraazacyclotetradecane (cyclam) rings connected through a 1,4-
dimethylene(phenylene) linker to the CXCR4 chemokine receptor was increased 7, 36, and 
50-fold, respectively, by incorporation of Cu2+, Zn2+, or Ni2+ into the cyclam rings of the 
compound. The rank order of the transition metal ions correlated with the calculated 
binding energy between free acetate and the metal ions coordinated in a cyclam ring. 
Construction of AMD3100 substituted with only a single Cu2+ or Ni2+ ion demonstrated that 
the increase in binding affinity of the metal ion substituted bicyclam is achieved through an 
enhanced interaction of just one of the ring systems. 
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Fig. 19. The 3D (a) and 2D (b) structure of AMD3100 (New Indications for AMD-3100, In: 
Drug Discovery Opinion,  2008; (Snell, 2005)] 
 
 
Fig. 20. Molecular model of the main ligand-binding pocket of the CXCR4 receptor with 
AMD3100(Zn) manually docked into favorable interactions with Asp171 in TM-IV and 
Asp262 in TM-VI. The receptor model is built over the rhodopsin model of Palcewski et al 
(Palczewski et al, 2000). The conformation of AMD3100 is based on structural requirements 
of high antiviral effects of AMD3100  and the crystallographic X-ray structure of 6,6’-
spirobis- (1,4,8,11-tetraazacyclotetradecane)-dinickel(II)tetraperchlorate, obtained from the 
Cambridge Structural Database (Gerlach et al, 2003). 
NH N
HNNH
NH HN
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Several low molecular weight nonpeptide compounds having the dipicolylamine-zinc(II) 
complex structure were also identified as potent and selective antagonists of the chemokine 
receptor CXCR4 (Tamamura et al, 2006). These compounds showed strong inhibitory 
activity against CXCL12 binding to CXCR4, and one of them (which has two sets of the 
[bis(pyridin-2-ylmethyl) amino]methylene unit with zinc(II) complexation at the para-
position of benzene) exhibited significant anti-HIV activity.   
The use of organometallic complexes are also investigated in the treatment of leishmania. 
The drugs for treating cutaneous lesions, or, in the case of visceral leishmaniasis (kala-
azar), caused by the species L. donovani or L. infantum have traditionally been 
pentavalent antimonials, aromatic diamidines and fungicides such as amphotericine B 
(Mesa-Valle et al, 1996). However, these are extremely toxic and cause a great number of 
side effects. Many recent efforts have been made to synthesize and evaluate alternative 
compounds for treating these parasites. In the last few years, certain metal complexes 
have proven anti-tumoral against such protozoan parasites as Trypanosoma cruzi, T. 
rhodesiense and L. donovani. One property that the tumor cells share with the 
trypanosomatids is rapid multiplication. Three organometallic complexes which have 
previously shown in vitro activity against the promastigote forms of L. donovani and 
have also shown a similar activity against the amastigote like forms, are Cis-
Pt(DDH)(Ac.19 2,5-Dihydroxi-benzensulphonic)2 and those of Rh(I): Rh(CO)2Cl(5Cl-2-
Methylbenzothiazole), Rh(CO)2Cl(2-Aminobenzothiazole) were investigated by Mesa-
Valle et al. (Mesa-Valle et al, 1996). In vitro toxicity of the complexes for the cells of the 
strain J-774 and the effect exerted on the parasite's biosynthesis of macromolecules were 
investigated. Only the Rh(I)(CO)2Cl(2-Aminobenzothiazole) complex induced substantial 
toxicity in the cells. The Rh(I)(CO)2Cl(5-Cl-2-Methylbenzothiazole) complex inhibited 
DNA, RNA, and protein synthesis. The best candidate, given its slight toxicity for 
mammal cells and its high activity against Leishmania by inhibiting the synthesis of 
macromolecules, is found as the complex Rh(I):Rh(CO)2Cl(5-Cl-2-Methylbenzothiazole). 
Croft et al. investigated the effect of 27 Platinum, Rhodium and Iridium drug complexes 
against Leishmania donovani amastigotes in mouse peritoneal macrophages in vitro 
(Croft et al, 1992). Rh(III)-mepacrine, Ir(III) pyrrolidine dithiocarbamate and Ir(III) diethyl 
dithiocarbamate which showed antileishmanial activity had ED50 values of less than 1 µM. 
The two Iridium complexes produced, respectively, a 50% and 39% suppression of L. 
donovani amastigotes in the liver of BALB/c mice following the subcutaneous 
administration of 200 mg/kg for 5 consecutive days. Ultrastructural studies suggest that 
the amastigote kinetoplast-mitochondrion complex is the primary site of action of the Ir 
and Rh complexes. Ir-(cycloocta-1,5-diene)-pentamidine tetraphenylborate which has 
previously been studied on promastigote forms of Leishmania, was investigated for its 
antileishmanial properties on Leishmania donovani and Leishmania major mouse models, 
compared with pentamidine used as reference compound in the year 2000 (Loiseau, et al, 
2000). In vitro, the iridium complex had the same IC50 value on intracellular forms of 
Leishmania as pentamidine (15 µM). In vivo, the compound could not be injected 
intravenously due to the DMSO excipient so that the treatments were performed 
intraperitoneally or subcutaneously. On the L. donovani LV9/Balb/C mouse model, the 
iridium complex was not toxic after intraperitoneal treatment at 232 mg/kg/day x 5 or 
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147 µmoles/kg/day x 5, whereas all the mice died within five days when treated at the 
same dose with pentamidine isethionate. However, only 23% of parasite suppression was 
observed with the iridium complex. On a L. major MON 74/Balb/C mouse model, 
susceptible to intravenously administered pentamidine at 6.7 µmoles/kg/day x 5 (54% of 
parasite suppression), the iridium complex exhibited 32% of parasite suppression after a 
treatment at 76 µmoles/kg/day x 5 administered subcutaneously. Transmission electron 
microscopy of amastigotes from infected and treated mice show aggregation of ribosomal 
material, distension of the nuclear membrane and kDNA depolymerization. The 
mechanism of action therefore involves several targets: membranes, ribosomes and 
kDNA. The researchers recommend the Iridium complex as a suitable candidate to be 
encapsulated in drug carriers such as liposomes or nanoparticles. 
Organometallic complexes of Pt, Rh, Ir, Pd, Os, have been synthesized and their 
trypanocidal activity was studied in vitro and in vivo by Loiseau (Loiseau et al, 1992). 
Among these, the Ir-(cycloocta-1,5-diene)-pentamidine complex, showed in vitro activity 
at 60 µg/L on Tripanosoma brucei brucei. Moreover, all infected mice were cured by this 
compound subcutaneously administered in a single dose at 0.5 mg/kg (0.317 µmol/kg). 
In the same conditions, pentamidine cured all the mice at 5 µmol/kg. Ir-(cycloocta-1,5-
diene)-pentamidine (or P1995) was 16 fold more efficient than pentamidine. Since the 
chemotherapeutic index of this molecule was 7.5 fold higher than those of pentamidine, 
the authors recommend P1995 to be considered as a potential trypanocidal drug of the 
future. 
Scientists are looking for alternative approaches for the treatment of diabetes. Several 
trace elements, such as vanadium and zinc, exert insulin-mimetic effects in in vitro and in 
vivo systems (Hiromura & Sakurai, 2008). The complexes of these metals and small 
organic compounds (ligands) improved glucose utilization in both diabetic model animals 
and human diabetic patients . Both vanadyl and zinc complexes enhanced glucose uptake 
into the adipocytes without the addition of any hormones. Under the same experimental 
conditions, these complexes inhibited epinephrine-induced free fatty acid (FFA) release. 
Because of this insulin-mimetic activity, oxovanadium(IV) (vanadyl) and zinc(II) (zinc) 
complexes are proposed to be potent antidiabetic agents for both type 1 and type 2 
Diabetes Mellitus therapy. New types of insulin-mimetic vanadyl and zinc complexes 
such as Bis(allixinato)oxovanadium(IV), [VO(alx)2], bis(allixinato)zinc(II) [Zn(alx)2], 
bis(thioallixin-N-methyl)zinc(II) [Zn(tanm)2] (Fig 21), were developed as the potent 
activators of the insulin signaling pathway. Although these complexes activate Akt/PKB, 
their critical action sites are slightly different from each other. Different action sites of the 
metal complexes may depend on the chemical characteristic of the vanadyl and zinc metal 
ions. The characteristic of ligand is important for the passing through the plasma 
membrane. VO(alx)2, Zn(alx)2, and Zn(tanm)2 also play unique roles in cells; VO(alx)2 
regulates the activation of the FoxO1, while Zn(alx)2 and Zn(tanm)2 regulate the activation 
of HSL (hormone-sensitive lipase), resulting in the suppression of free fatty acid release. 
The common mechanism of action of VO(alx)2, Zn(alx)2, and Zn(tanm)2 is their effect on 
the insulin signaling pathway; this in turn regulates gene transcription and suppresses 
lipolysis signaling.  
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Fig. 21. The molecular structures of VO(alx)2, Zn(alx)2, and Zn(tanm)2 (Hiromura & Sakurai, 
2008) 
Another application of organometallic complexes is antiinflammatory therapy. Numerous 
Cu(II) complexes of NSAIDs with enhanced anti-inflammatory activity and reduced 
gastrointestinal (GI) toxicity compared with their uncomplexed parent drug, were 
developed (Hiromura & Sakurai, 2008). No Cu(II) anti-inflammatory drug is currently 
available for oral human use, although an ethanolic gel-base of Cu-salicylate (Alcusal®) is 
available for topical temporal relief of pain and inflammation in humans (Weder et al, 2002). 
A Cu(II) dimer of indomethacin (IndoH_/1- (4-chlorobenzoyl)-5-methoxy-2-methyl-1H-
Indole-3-acetic acid) with low toxicity is commercially available in Australasia, South East 
Asia and South Africa in a variety of oral pharmaceutical dosage forms for veterinary use. 
These low toxicity Cu drugs are of enormous interest, because many of today’s anti-
inflammatory drug therapies, including the NSAIDs, remain either largely inadequate 
and/or are associated with problematic side effects, e.g. renal insufficiency and failure, GI 
ulceration, bleeding or perforation (‘NSAID gastropathy’), exacerbation of hypertension  
and congestive heart failure (CHF). Sorenson reported that Cu(II)-complexes of these 
antiinflammatory drugs were more active in animal models than either their parent 
inorganic Cu(II) salt or the parent NSAID . The pharmacological activity was proposed to be 
due to the inherent physico-chemical properties of the complex itself rather than just that of 
its constituents, since the amount of Cu(II) in such complexes does not correlate with anti-
inflammatory activity. Sorenson reported that a salicylate complex of Cu(II) was ≈30 times 
more effective than aspirin as an anti-inflammatory agent. In two previous reviews, 
Sorenson reported over 140 Cu(II) complexes with anti-inflammatory activity. However, 
limited information is available on the nature of the Cu complexes of NSAIDs in biological 
matrices and in pharmaceutical formulations. SOD activity, redox behavior, lipophilicity 
and stability constants may be useful parameters in evaluating the biological activity of 
these Cu compounds. 
The proposed curative properties of Cu-based nonsteroidal anti-inflammatory drugs 
(NSAIDs) have led to the development of numerous Cu(II) complexes of NSAIDs with 
enhanced anti-inflammatory activity (Trinchero et al, 2004) Crystalline complexes, Cu(II)–
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NSAID (ibuprofen, naproxen, tolmetin, and diclofenac), with a carboxylic function have 
been studied by means of infrared and Raman spectroscopy. All NSAIDs bind to the metal 
through the carboxylate group. The spectroscopic data support the formation of dimeric 
[Cu2L4(H2O)2] complexes in which the COO- group behaves as a bridging bidentate ligand. 
The preparation and properties of the Cu(II) complex Cu(SAS)2.H2O are reported for the 
antiinflammatory drug Salsalate (SAS) (Underhill et al, 1989). The complex is reported to 
exhibit an increased superoxide dismutase activity compared with the parent drug molecule 
in the nitroblue tetrazolium assay. Weder and friends synthesized Cu(II) indomethacin 
complexes (Weder  et al, 1999). 
Drugs belonging to the non-steroidal anti-inflammatory drug group (NSAID) are not only 
used as anti-inflammatory and analgesic agents, but also exhibit chemopreventive and 
chemosuppressive effects on various cancer cell lines  (Roy et al, 2006). They exert their 
anticancer effects by inhibiting both at the protein level and/or at the transcription level. Cu(II) 
complexes of these NSAIDs show better anti-cancer effects than the bare drugs. UV-Visible 
spectroscopy was used to characterize the complexation between Cu(II) and two NSAIDs 
belonging to the oxicam group, piroxicam and meloxicam, both of which exhibit anticancer 
properties. For the first time, this study shows that, Cu(II)-NSAID complexes can directly bind 
with the DNA backbone, and the binding constants and the stoichiometry or the binding site 
sizes have been determined. Thermodynamic parameters from van't Hoff plots showed that 
the interaction of these Cu(II)-NSAID complexes with ctDNA is an entropically driven 
phenomenon. Circular dichroism spectroscopy showed that the binding of these Cu(II)-
NSAIDs with ctDNA result in DNA backbone distortions which is similar for both Cu(II)-
piroxicam and Cu(II)-meloxicam complexes. Competitive binding with a standard intercalator 
like ethidium bromide (EtBr) investigated by circular dichroism spectroscopy as well as 
fluorescence measurements indicate that the Cu(II)-NSAID complexes could intercalate in the 
DNA. 
Inspired from Sorenson’s studies, new investigations on formation and synthesis of Cu(II) 
complexes with antiinflammatory drugs were carried out as well as Zn(II) complexes, where 
some of them are ternary complexes (Anılanmert et al, 2010).  The formation conditions and 
constants of Cu(II)-tryptophan-aspirin and Zn(II)-tryptophan-aspirin ternary complexes in 
aqueous solutions were determined using potentiometric method to provide chemical data 
for the synthesis, considering the synergistic capability of aspirin, the antiinflammatory 
activity of Cu(II), the synergistic effect of tryptophan-aspirin combination in migraine and in 
diseases which cause immune activation, the stronger analgesic, antiinflammatory and 
antithrombotic effect of Cu(II)-aspirinate and Zn(II)-aspirinate than aspirin, decreased 
gastrointestinal toxicity of Cu(II)-aspirinate and Zn(II)-aspirinate than aspirin, the stronger 
analgesic and antiinflammatory effects of some Cu(II)-amino acid complexes than Cu(II)-
aspirinate and the increased bioavailability of Zn(II)-amino acid complexes. The effects of 
leucine in cancer, wound healing and regulation of glucose in blood, anticancer activity and 
healing activity of Cu(II) on radiation effects, antiinflammatory effects of Cu(II)-aspirin and 
Cu(II)-amino acid compounds, sinergistic activity of aspirin and its anticancer effect which 
was proved in recent years are known (Anılanmert, 2006). Under the light of these effects, 
the formation of Cu(II)-leucine-aspirin was also investigated using potentiometric and 
spectrophotometric method. The anticancer action and wound healing effect on skin cancers 
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topically and through injection into tumours should be investigated in the future. These 
ternary complexes have only been investigated using potentiometry, UV and IR 
spectrometry, synthesis studies are going on, yet no in vitro and in vivo study is performed, 
however they are recommended to be investigated for the above therapeutic effects. 
3. Conclusion 
In this chapter, clinical uses of organometallic complexes and some prominent studies on 
new therapeutic complexes were mentioned. Developments in explorations of 
organometallic compounds, in various therapeutic areas continue to be an active and 
productive area of research. Increasingly powerful tools, notably spectroscopic techniques 
like time-resolved infrared are used for identifying and structurally characterizing the solid 
complex, optical spectroscopic and potentiometric methods are used for monitoring 
intermediates and species in solution. Besides these preclinical and clinical studies are 
significantly enhancing our knowledge and understanding of  the structure and mechanistic 
aspects of the therapeutic organometallic complexes. 
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